WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 575196
CAS#: 866598-45-0
Description: AZD-2207 is a cannabinoid receptor CB1 antagonist and highly lipophilic compound for the treatment of type 2 diabetes mellitus and obesity.
MedKoo Cat#: 575196
Name: AZD-2207
CAS#: 866598-45-0
Chemical Formula: C25H25Cl2F3N4O4S
Exact Mass: 604.0926
Molecular Weight: 605.4542
Elemental Analysis: C, 49.59; H, 4.16; Cl, 11.71; F, 9.41; N, 9.25; O, 10.57; S, 5.30
Synonym: AZD-2207; AZD2207; AZD 2207
IUPAC/Chemical Name: 1-Propanesulfonic acid, 3,3,3-trifluoro-, 4-(2-(2,4-dichlorophenyl)-5-methyl-4-((1-piperidinylamino)carbonyl)-1H-imidazol-1-yl)phenyl ester
InChi Key: NHIXRYPUVCFFAF-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H25Cl2F3N4O4S/c1-16-22(24(35)32-33-12-3-2-4-13-33)31-23(20-10-5-17(26)15-21(20)27)34(16)18-6-8-19(9-7-18)38-39(36,37)14-11-25(28,29)30/h5-10,15H,2-4,11-14H2,1H3,(H,32,35)
SMILES Code: Cc1c(nc(c2ccc(Cl)cc2Cl)n1c3ccc(OS(=O)(=O)CCC(F)(F)F)cc3)C(=O)NN4CCCCC4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | AZD-2207 is a cannabinoid receptor CB1 antagonist. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
The following data is based on the product molecular weight 605.4542 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1. Tannergren C, Karlsson E, Sigfridsson K, Lindfors L, Ku A, Polentarutti B, Carlert S. Biopharmaceutic Profiling of Salts to Improve Absorption of Poorly Soluble Basic Drugs. J Pharm Sci. 2016 Nov;105(11):3314-3323. doi: 10.1016/j.xphs.2016.07.016. Epub 2016 Sep 13. PMID: 27637320.
2. Kourentas A, Vertzoni M, Barmpatsalou V, Augustijns P, Beato S, Butler J, Holm R, Ouwerkerk N, Rosenberg J, Tajiri T, Tannergren C, Symillides M, Reppas C. The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. AAPS J. 2018 May 24;20(4):71. doi: 10.1208/s12248-018-0231-8. PMID: 29797293.
